AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25346896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, n=30)
Number of subjects: 90
Study 22052885 — intervention group
Group type: EXPERIMENTAL
Intervention: AmB (0.7-1 mg/kg) and 5-FC (25 mg/kg 4 times daily)
Number of subjects: 80
Study 22052885 — intervention group
Group type: EXPERIMENTAL
Intervention: AmB (0.7-1 mg/kg) and fluconazole (800 mg daily)
Number of subjects: 80
Study 22052885 — intervention group
Group type: EXPERIMENTAL
Intervention: AmB (0.7-1 mg/kg) and fluconazole (600 mg twice daily)
Number of subjects: 80
Study 22052885 — intervention group
Group type: EXPERIMENTAL
Intervention: AmB (0.7-1 mg/kg) and voriconazole (300 mg twice daily)
Number of subjects: 80
Study 20193727 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-acid modified resin composite/resin composite sandwich restoration
Number of subjects: 29
Study 20193727 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct resin composite restoration
Number of subjects: 29
Study 20193727 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminate restoration
Number of subjects: 29
Study 17397426 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 150
Study 17397426 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Safety Assessment and Modification (HSAM)
Number of subjects: 150
Study 15614689 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic containing Bifidobacterium bifidum BB‐02 and Bifidobacterium lactis BL‐01 with inulin-based prebiotic (Synergy 1; Orafti)
Number of subjects: 18
Study 15614689 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic consumption
Number of subjects: 18
Study 15614689 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic feeding
Number of subjects: 18
Study 11408002 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients with nephropathy
Number of subjects: 35
Study 11408002 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients without nephropathy
Number of subjects: 35
Study 11408002 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 35
Study 11408002 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetic patients with retinopathy
Number of subjects: 35
Study 9409334 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 586
Study 9409334 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg
Number of subjects: 586
Study 9409334 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 0.25 mg
Number of subjects: 586
Study 9409334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 9409334 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg and 1 mg
Number of subjects: 586
Study 9409334 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan
Number of subjects: 586
Study 9409334 — intervention group
Group type: COMPARATOR
Intervention: Naratriptan and placebo
Number of subjects: 586
Study 8202976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory stimulation (including electrostimulation)
Number of subjects: 78
Study 8202976 — intervention group
Group type: COMPARATOR
Intervention: Control (same physiotherapy and occupational therapy)
Number of subjects: 78
Study 3308647 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal gas tamponade without episcleral buckle
Number of subjects: 120
Study 3308647 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy
Number of subjects: 120
Study 31288906 — intervention group
Group type: EXPERIMENTAL
Intervention: No chest tube (NCT group)
Number of subjects: 74
Study 31288906 — intervention group
Group type: COMPARATOR
Intervention: Chest tube (CT group)
Number of subjects: 74
Study 28432049 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowed aspirin taken simultaneously with niacin
Number of subjects: 0
Study 28432049 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally dissolved aspirin taken simultaneously with niacin
Number of subjects: 0
Study 28432049 — intervention group
Group type: EXPERIMENTAL
Intervention: Both orally dissolved and swallowed aspirin taken simultaneously with niacin
Number of subjects: 0
Study 28432049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25403142 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed using the Patient Health Questionnaire‐9 (PHQ‐9)
Number of subjects: 286
Study 25403142 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessed using the Short Form McGill Pain Questionnaire (SF‐MPQ)
Number of subjects: 286
Study 24130254 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Care Trial (PCT) recruitment protocol
Number of subjects: 461
Study 20880286 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg bee pollen/kg BW
Number of subjects: 40
Study 20880286 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg bee pollen/kg BW
Number of subjects: 40
Study 20880286 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg bee pollen/kg BW
Number of subjects: 40
Study 20880286 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg bee pollen/kg BW)
Number of subjects: 40
Study 19660800 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuidex (mid-urethral injection)
Number of subjects: 344
Study 19660800 — intervention group
Group type: COMPARATOR
Intervention: Contigen (proximal urethral cystoscopic injection)
Number of subjects: 344
Study 16883093 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine
Number of subjects: 685
Study 16883093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 685
Study 16883093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine
Number of subjects: 685
Study 16883093 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine
Number of subjects: 685
Study 16883093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 685
Study 16883093 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 685
Study 16883093 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide
Number of subjects: 685
Study 16883093 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment
Number of subjects: 685
Study 14759446 — intervention group
Group type: EXPERIMENTAL
Intervention: HSD solution (4 mL/kg during 20 minutes before cardiopulmonary bypass)
Number of subjects: 50
Study 14759446 — intervention group
Group type: COMPARATOR
Intervention: Ringer solution (same volume as HSD)
Number of subjects: 50
Study 11726445 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered using TCI at target concentrations of 1.5-4.5 microg/mL to pregnant women.
Number of subjects: 72
Study 11726445 — intervention group
Group type: COMPARATOR
Intervention: Propofol administered using TCI at target concentrations of 1.5-4.5 microg/mL to nonpregnant women.
Number of subjects: 72
Study 9212372 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent competence enhancement intervention (MCEI)
Number of subjects: 309
Study 9212372 — intervention group
Group type: COMPARATOR
Intervention: Information/attention control (IAC)
Number of subjects: 309
Study 8424001 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing
Number of subjects: 31
Study 8424001 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing in obese children
Number of subjects: 31
Study 8424001 — intervention group
Group type: COMPARATOR
Intervention: Resting energy expenditure
Number of subjects: 31
Study 3664551 — intervention group
Group type: EXPERIMENTAL
Intervention: Shampoo (pyrethrin-piperonyl-butoxide)
Number of subjects: 40
Study 3664551 — intervention group
Group type: COMPARATOR
Intervention: Lotion (pyrethrin-piperonyl-butoxide)
Number of subjects: 40
Study 29258890 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (30 mg)
Number of subjects: 29
Study 29258890 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg)
Number of subjects: 29
Study 29258890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 27436332 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored ANBL program
Number of subjects: 463
Study 27436332 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored current best practices (CBP)
Number of subjects: 463
Study 26424673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Number of subjects: 484
Study 26424673 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir 800 mg plus ritonavir 100 mg
Number of subjects: 484
Study 22895370 — intervention group
Group type: EXPERIMENTAL
Intervention: 30G + MOD (30 g of glucose preexercise)
Number of subjects: 11
Study 22895370 — intervention group
Group type: COMPARATOR
Intervention: 0G + MOD (0 g of glucose preexercise)
Number of subjects: 11
Study 22895370 — intervention group
Group type: EXPERIMENTAL
Intervention: 0G + MOD/INT (0 g of glucose preexercise with high-intensity intervals)
Number of subjects: 11
Study 21718512 — intervention group
Group type: EXPERIMENTAL
Intervention: Website only
Number of subjects: 306
Study 21718512 — intervention group
Group type: EXPERIMENTAL
Intervention: Website with peer-led support
Number of subjects: 306
Study 21718512 — intervention group
Group type: EXPERIMENTAL
Intervention: Website with professional email-counseling
Number of subjects: 306
Study 21718512 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 306
Study 18645518 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-delivered intervention
Number of subjects: 152
Study 18645518 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 152
Study 16527680 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating occlusion (full time and symmetric for those with no amblyopia, asymmetric for those with amblyopia)
Number of subjects: 44
Study 16527680 — intervention group
Group type: COMPARATOR
Intervention: Control group (occlusion for amblyopia only)
Number of subjects: 44
Study 12872052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (low-dose diuretic)
Number of subjects: 392
Study 12872052 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (angiotensin-II-receptor blocker)
Number of subjects: 392
Study 11119182 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention
Number of subjects: 228
Study 11119182 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 228
Study 7640592 — intervention group
Group type: COMPARATOR
Intervention: General practitioners
Number of subjects: 1702
Study 7640592 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior house officers
Number of subjects: 1702
Study 7640592 — intervention group
Group type: EXPERIMENTAL
Intervention: Registrars
Number of subjects: 1702
Study 2508341 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-baths with high CO2-concentration
Number of subjects: 423
Study 2508341 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-baths with low CO2-concentration
Number of subjects: 423
Study 2508341 — intervention group
Group type: COMPARATOR
Intervention: CO2-baths (both high and low concentration)
Number of subjects: 423
Study 31851795 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab (300 mg) every 4 weeks for 48 weeks
Number of subjects: 362
Study 31851795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 31234927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab and chemotherapy (n=82)
Number of subjects: 163
Study 31234927 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy (control group; n=81)
Number of subjects: 163
Study 27796604 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS plus occupational therapy
Number of subjects: 23
Study 27796604 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS plus occupational therapy
Number of subjects: 23
Study 25969155 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF/5% TMP varnish
Number of subjects: 12
Study 25969155 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaF varnish
Number of subjects: 12
Study 25969155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no F or TMP)
Number of subjects: 12
Study 24949710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 12
Study 24949710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21723639 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention training (30 min) while taking big steps and performing serial three subtractions
Number of subjects: 12
Study 21723639 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention training (30 min)
Number of subjects: 12
Study 21723639 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 12
Study 19615959 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic dairy drink containing Lactobacillus casei DN-114 001 and yoghurt ferments (Actimel), consumed twice daily for 7 weeks (pilot) or 13 weeks (confirmatory).
Number of subjects: 308
Study 19615959 — intervention group
Group type: COMPARATOR
Intervention: Non-fermented control dairy product, consumed twice daily for 7 weeks (pilot) or 13 weeks (confirmatory).
Number of subjects: 308
Study 19615959 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic dairy drink (Actimel).
Number of subjects: 308
Study 17250579 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of periodontal dressing to sensitive teeth
Number of subjects: 22
Study 17250579 — intervention group
Group type: COMPARATOR
Intervention: No periodontal dressing (control)
Number of subjects: 22
Study 15710008 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anaesthesia
Number of subjects: 2251
Study 15710008 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 2251
Study 12665918 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg once a day for one year
Number of subjects: 94
Study 12665918 — intervention group
Group type: COMPARATOR
Intervention: Common liver protection drugs
Number of subjects: 94
Study 9699124 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.1 IU/Kg i.m. for 3 days
Number of subjects: 18
Study 9699124 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 18
Study 9699124 — intervention group
Group type: COMPARATOR
Intervention: Pure FSH (75 IU)
Number of subjects: 18
Study 9699124 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 18
Study 8519676 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin + Amifostine (CA arm)
Number of subjects: 21
Study 8519676 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin alone (C arm)
Number of subjects: 21
Study 1683503 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide 0.05 mg
Number of subjects: 19
Study 1683503 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine 2.5 mg
Number of subjects: 19
Study 1683503 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide (incremental doses for 6 months)
Number of subjects: 19
Study 1683503 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (incremental doses for 6 months)
Number of subjects: 19
Study 7055053 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial 60-degree LAO view
Number of subjects: 36
Study 7055053 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial 45-degree RAO view
Number of subjects: 36
Study 7055053 — intervention group
Group type: COMPARATOR
Intervention: Conventional 30-degree RAO/60-degree LAO projection
Number of subjects: 36
Study 30218226 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions including the use of tongue scraper
Number of subjects: 36
Study 30218226 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions alone without tongue cleaning
Number of subjects: 36
Study 28945850 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 296
Study 28945850 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/pemetrexed plus pemetrexed maintenance
Number of subjects: 296
Study 25784519 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily for 8 days starting 48 hours before surgery)
Number of subjects: 59
Study 25784519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 25784519 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 59
Study 22626867 — intervention group
Group type: EXPERIMENTAL
Intervention: Left anodal tDCS
Number of subjects: 20
Study 22626867 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 22626867 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective mood and anxiety evaluation
Number of subjects: 20
Study 21484242 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 0
Study 21484242 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 0
Study 21484242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21484242 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 0
Study 19137320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ISMN gel
Number of subjects: 52
Study 19137320 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% GTN gel
Number of subjects: 52
Study 19137320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 17700043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular repositioning appliance (MRA)
Number of subjects: 50
Study 14995003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (IVCYC) 0.5 g/m² body surface area, monthly
Number of subjects: 34
Study 14995003 — intervention group
Group type: COMPARATOR
Intervention: Oral enalapril 10 mg/day
Number of subjects: 34
Study 11483846 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (0.016 mg/kg/IgE [IU/mL] per 4 weeks)
Number of subjects: 334
Study 11483846 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 334
Study 11483846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 9608348 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent take-home medication doses during baseline (8-week duration)
Number of subjects: 0
Study 9608348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg take-home doses during contingency management
Number of subjects: 0
Study 9608348 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 0 mg and 20 mg take-home doses during contingency management
Number of subjects: 0
Study 8107741 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (1.5 million units thrice weekly for 1 week, then 3 million units thrice weekly for 23 weeks)
Number of subjects: 53
Study 8107741 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional treatment apart from previously prescribed treatments)
Number of subjects: 53
Study 8107741 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a
Number of subjects: 53
Study 8107741 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (resumption of treatment)
Number of subjects: 53
Study 2532624 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dentine-enamel adhesive (ferric oxalate, N‐phenylglycine, PMDM)
Number of subjects: 0
Study 2532624 — intervention group
Group type: COMPARATOR
Intervention: Light-cured Scotch-bond
Number of subjects: 0
Study 2532624 — intervention group
Group type: COMPARATOR
Intervention: ZOE (Zinc Oxide Eugenol)
Number of subjects: 0
Study 4886628 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 30
Study 4886628 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 30
Study 4886628 — intervention group
Group type: COMPARATOR
Intervention: Arvin
Number of subjects: 30
Study 30822358 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic therapies (ustekinumab) in RCTs
Number of subjects: 8811
Study 30822358 — intervention group
Group type: COMPARATOR
Intervention: Real-world populations on biologic therapies
Number of subjects: 8811
Study 28686199 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI breakfast (64.0 GI and 1318 KJ energy)
Number of subjects: 40
Study 28686199 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI breakfast (29.4 GI and 1489 KJ energy)
Number of subjects: 40
Study 28686199 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (only water)
Number of subjects: 40
Study 26700981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (two 200-μg tablets every 4 hours for up to 48 hours)
Number of subjects: 195
Study 26700981 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (two 200-μg tablets inserted every 4 hours for 48 hours)
Number of subjects: 195
Study 26700981 — intervention group
Group type: COMPARATOR
Intervention: Combination route (two 200-μg tablets vaginally followed by 400 μg sublingually every 4 hours for 48 hours)
Number of subjects: 195
Study 23389691 — intervention group
Group type: EXPERIMENTAL
Intervention: GABAergic mechanism involvement in the ventromedial prefrontal cortex (vmPFC) during aversive-aversive stimulus interaction
Number of subjects: 0
Study 23389691 — intervention group
Group type: EXPERIMENTAL
Intervention: GABAA receptors in vmPFC and sensorimotor cortex
Number of subjects: 0
Study 21848959 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of pure ethanol/kg of body weight (low dose: LD)
Number of subjects: 10
Study 21848959 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g of pure ethanol/kg of body weight (high dose: HD)
Number of subjects: 10
Study 21848959 — intervention group
Group type: COMPARATOR
Intervention: 0 g of pure ethanol/kg of body weight (control)
Number of subjects: 10
Study 18089452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 2103
Study 16760409 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL3 production in infants born to HIV-positive mothers
Number of subjects: 0
Study 16760409 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL3 production in infants who acquired HIV-1 infection
Number of subjects: 0
Study 16760409 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL3-L1 gene copy number
Number of subjects: 0